PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Naltrexone; as an efficient adjuvant in induction of Th1 immunity and protection against Fasciola hepatica infection.

Abstract Toxic effects of available therapeutics are major drawbacks for conventional management approaches in parasitic infections. Vaccines have provided a promising opportunity to obviate such unwanted complications. In present study, we examined immune augmenting capacities of an emerging adjuvant, Naltrexone, against Fasciola hepatica infection in BALB/c mice. Seventy BALB/c mice were divided into five experimental groups (14 mice per group) including 1- control (received PBS), 2- vaccine (immunized with F. hepatica E/S antigens), 3- Alum-vaccine (immunized with Alum adjuvant and E/S antigens), 4- NLT-vaccine (immunized with NLT adjuvant and E/S antigens), and 5- Alum-NLT-vaccine (immunized with mixed Alum-NLT adjuvant and E/S antigens). Lymphocyte stimulation index was assessed by MTT assay. Production of IFN-γ, IL-4, IgG2a and IgG1 was assessed by ELISA method. Results showed that NLT, either alone or in combination with alum, can induce immune response toward production of IFN-γ and IgG2a as representatives of Th1 immune response. Also, using this adjuvant in immunization experiment was associated with significantly high proliferative response of splenocytes/lymphocytes. Utilization of mixed Alum-NLT adjuvant revealed the highest protection rate (73.8%) in challenge test of mice infected with F. hepatica. These findings suggest the potential role of NLT as an effective adjuvant in induction of protective cellular and Th1 immune responses against fasciolosis.
PMID
Related Publications

Evaluation of hepatic changes and local and systemic immune responses in goats immunized with recombinant Peroxiredoxin (Prx) and challenged with Fasciola hepatica.

A novel adjuvant, mixture of Alum and naltrexone, elicits humoral immune responses for excreted/secreted antigens of Toxoplasma gondii tachyzoites vaccine in Balb/c murine model.

Adjuvant-enhanced antibody and cellular responses to inclusion bodies expressing FhSAP2 correlates with protection of mice to Fasciola hepatica.

Mixture of Alum--Naloxone and Alum--Naltrexone as a novel adjuvant elicits immune responses for Toxoplasma gondii lysate antigen in BALB /c mice.

A novel adjuvant, the mixture of alum and naltrexone, augments vaccine-induced immunity against Plasmodium berghei.

Authors

Mayor MeshTerms
Keywords

Alum

Fasciola hepatica

Fasciolosis

Naltrexone

Vaccination

Journal Title experimental parasitology
Publication Year Start




PMID- 29729492
OWN - NLM
STAT- MEDLINE
DCOM- 20180529
LR  - 20180529
IS  - 1090-2449 (Electronic)
IS  - 0014-4894 (Linking)
VI  - 189
DP  - 2018 Jun
TI  - Naltrexone; as an efficient adjuvant in induction of Th1 immunity and protection 
      against Fasciola hepatica infection.
PG  - 66-71
LID - S0014-4894(17)30508-8 [pii]
LID - 10.1016/j.exppara.2018.04.015 [doi]
AB  - Toxic effects of available therapeutics are major drawbacks for conventional
      management approaches in parasitic infections. Vaccines have provided a promising
      opportunity to obviate such unwanted complications. In present study, we examined
      immune augmenting capacities of an emerging adjuvant, Naltrexone, against
      Fasciola hepatica infection in BALB/c mice. Seventy BALB/c mice were divided into
      five experimental groups (14 mice per group) including 1- control (received PBS),
      2- vaccine (immunized with F. hepatica E/S antigens), 3- Alum-vaccine (immunized 
      with Alum adjuvant and E/S antigens), 4- NLT-vaccine (immunized with NLT adjuvant
      and E/S antigens), and 5- Alum-NLT-vaccine (immunized with mixed Alum-NLT
      adjuvant and E/S antigens). Lymphocyte stimulation index was assessed by MTT
      assay. Production of IFN-gamma, IL-4, IgG2a and IgG1 was assessed by ELISA
      method. Results showed that NLT, either alone or in combination with alum, can
      induce immune response toward production of IFN-gamma and IgG2a as
      representatives of Th1 immune response. Also, using this adjuvant in immunization
      experiment was associated with significantly high proliferative response of
      splenocytes/lymphocytes. Utilization of mixed Alum-NLT adjuvant revealed the
      highest protection rate (73.8%) in challenge test of mice infected with F.
      hepatica. These findings suggest the potential role of NLT as an effective
      adjuvant in induction of protective cellular and Th1 immune responses against
      fasciolosis.
CI  - Copyright (c) 2018 Elsevier Inc. All rights reserved.
FAU - Azizi, Hakim
AU  - Azizi H
AD  - Department of Medical Parasitology, School of Medicine, Zabol University of
      Medical Sciences, Zabol, Iran.
FAU - Mirzaeei, Hadi
AU  - Mirzaeei H
AD  - Department of Medical Genetics, School of Medicine, Zabol University of Medical
      Sciences, Zabol, Iran.
FAU - Nasiri, Ali Akbar
AU  - Nasiri AA
AD  - Department of Anesthesiology, Zabol University of Medical Sciences, Zabol, Iran.
FAU - Bazi, Ali
AU  - Bazi A
AD  - Clinical Research Development Unit, Zabol University of Medical Sciences, Zabol, 
      Iran.
FAU - Mirzapour, Aliyar
AU  - Mirzapour A
AD  - Department of Medical Parasitology, School of Medicine, Shahid Beheshti
      University of Medical Sciences, Tehran, Iran.
FAU - Khatami, Mehrdad
AU  - Khatami M
AD  - School of Medicine, Bam University of Medical Sciences, Bam, Iran.
FAU - Nahavandi, Kareem Hatam
AU  - Nahavandi KH
AD  - Infectious Diseases and Tropical Medicine Research Center, Zahedan University of 
      Medical Sciences, Zahedan, Iran.
FAU - Azimi, Ako
AU  - Azimi A
AD  - Maragheh University of Medical Sciences, Department of Basic Sciences, Maragheh, 
      Iran.
FAU - Yaghoobi, Hajar
AU  - Yaghoobi H
AD  - Cellular and Molecular Research Center, Basic Health Sciences Institute,
      Shahrekord University of Medical Sciences, Shahrekord, Iran. Electronic address: 
      [email protected]
LA  - eng
PT  - Journal Article
DEP - 20180427
PL  - United States
TA  - Exp Parasitol
JT  - Experimental parasitology
JID - 0370713
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Alum Compounds)
RN  - 0 (Antibodies, Helminth)
RN  - 0 (Immunoglobulin G)
RN  - 0 (Viral Vaccines)
RN  - 207137-56-2 (Interleukin-4)
RN  - 34S289N54E (aluminum sulfate)
RN  - 5S6W795CQM (Naltrexone)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Adjuvants, Immunologic/administration & dosage/pharmacology/*therapeutic use
MH  - Alum Compounds/administration & dosage/pharmacology/therapeutic use
MH  - Animals
MH  - Antibodies, Helminth/blood
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Fasciola hepatica/drug effects/*immunology
MH  - Fascioliasis/drug therapy/immunology/*prevention & control
MH  - Female
MH  - Immunity, Cellular/drug effects
MH  - Immunization
MH  - Immunoglobulin G/blood
MH  - Interferon-gamma/analysis
MH  - Interleukin-4/analysis
MH  - Lymphocyte Activation
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Naltrexone/administration & dosage/pharmacology/*therapeutic use
MH  - Random Allocation
MH  - Sheep
MH  - Th1 Cells/drug effects/*immunology
MH  - Viral Vaccines/administration & dosage
OTO - NOTNLM
OT  - Alum
OT  - Fasciola hepatica
OT  - Fasciolosis
OT  - Naltrexone
OT  - Vaccination
EDAT- 2018/05/08 06:00
MHDA- 2018/05/31 06:00
CRDT- 2018/05/06 06:00
PHST- 2017/09/20 00:00 [received]
PHST- 2018/04/08 00:00 [revised]
PHST- 2018/04/15 00:00 [accepted]
PHST- 2018/05/08 06:00 [pubmed]
PHST- 2018/05/31 06:00 [medline]
PHST- 2018/05/06 06:00 [entrez]
AID - S0014-4894(17)30508-8 [pii]
AID - 10.1016/j.exppara.2018.04.015 [doi]
PST - ppublish
SO  - Exp Parasitol. 2018 Jun;189:66-71. doi: 10.1016/j.exppara.2018.04.015. Epub 2018 
      Apr 27.